Clinical Trial Update: Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tiotropium delivered by the Respimat inhaler as add-on therapy in adults with severe persistent asthma; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Spiriva (tiotropium) (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2012-09-27